This technology presents a series of novel small molecule compounds that target a key regulatory protein implicated in HIV progression. The compounds were discovered through a high-throughput screening assay linking viral accessory protein activity with a specific kinase activation. They exhibit low micromolar potency in inhibiting the related kinase activity induced by the viral protein while exerting minimal impact on the kinase itself. Additionally, they demonstrate submicromolar effectiveness against HIV replication in primary human macrophages, with confirmed direct binding via surface plasmon resonance and low toxicity across tested models.